This study examines clinical characteristics and antibody responses among pregnant women infected with Omicron variants in China from December 2022 to April 2023. Researchers investigated 223 pregnant women with at least six weeks gestation and 31 healthy controls to evaluate humoral immune responses following natural SARS-CoV-2 infection, particularly in those previously vaccinated with inactivated vaccines. The research addresses critical knowledge gaps regarding how immune imprinting from inactivated vaccines may influence cross-neutralization against emerging Omicron subvariants. This cross-sectional investigation provides important insights into pregnancy-specific immune dynamics during COVID-19 infection and vaccine responses, contributing valuable data for understanding maternal and fetal health implications during the pandemic.

HLA-C is a major histocompatibility complex class I gene in humans, identified as Gene ID 3107 in the National Center for Biotechnology Information database. This gene encodes a protein involved in the immune system's ability to present antigens to T cells, playing a crucial role in immune recognition and response. Located within the human genome, HLA-C is essential for transplant compatibility assessment, disease susceptibility studies, and understanding immune-mediated conditions. The NCBI database provides comprehensive genomic data, including sequencing information, expression profiles, and mapped phenotypes associated with HLA-C variants, supporting clinical and research applications in immunology and precision medicine.

This study presents an innovative computational framework for optimizing therapeutic mRNA sequences by combining deep learning with evolutionary algorithms. Researchers employ a pretrained CodonTransformer to generate initial mRNA candidates, followed by a genetic algorithm that iteratively refines sequences through codon-aware modifications. The optimization targets multiple critical parameters: translation efficiency metrics including codon adaptation index and tRNA adaptation index, structural stability through mRNA secondary structure analysis, and reduced immunogenic potential by minimizing problematic motif frequencies. Results demonstrate substantial improvements across successive generations, achieving enhanced codon adaptation and tRNA matching while maintaining stable secondary structures and low immunogenicity. This integrated approach offers a promising alternative to existing mRNA design methodologies for developing safer and more effective therapeutic vaccines and treatments.

Artificial intelligence-directed computational protein design has revolutionized therapeutic discovery, particularly for vaccines and antibody-based treatments against infectious diseases. The COVID-19 pandemic demonstrated both the transformative potential and significant limitations of these technologies. AI-driven approaches successfully accelerated viral characterization, vaccine development, and broadly neutralizing antibody design. However, critical challenges emerged, including data bias, model interpretability issues, experimental validation bottlenecks, and regulatory framework integration gaps. The pandemic revealed a crucial disconnect between computational promise and translational readiness, necessitating closer collaboration between computational design, laboratory experimentation, and clinical evaluation. Additionally, rapid AI innovation has outpaced established regulatory pathways, highlighting the need for enhanced oversight mechanisms before these technologies can serve as reliable pandemic preparedness cornerstones.

This review examines the application of machine learning and artificial intelligence in predicting immunogenicity risks associated with biologic therapies during preclinical development. Anti-drug antibodies resulting from unwanted immune responses pose significant challenges to clinical development and patient outcomes. Currently, predicting immunogenicity before clinical trials remains impossible due to immune system complexity and multiple contributing factors. However, advances in computational methods offer promising opportunities for improved prediction accuracy. Industry experts and academics convened at an EMBL-EBI workshop to assess AI and ML contributions to immunogenicity prediction, review current industry practices, and identify future opportunities for deploying these transformative technologies in therapeutic development.

People vaccinated against COVID in Germany in 2023 experienced reduced hospitalization rates, fewer long-COVID diagnoses, and lower all-cause mortality than those who weren't vaccinated, according to a new study published in Eurosurveillance. These clinical benefits translated to significant reductions in health care costs and lost productivity due to sick leave.

The World Health Organization is monitoring BA.3.2, a new COVID-19 variant circulating across the United States as warmer temperatures approach. This variant, a descendant of Omicron, has been detected in 31 states and raises concerns about its potential to evade immunity from prior vaccination or infection due to modifications in its spike protein. Dr. Sonia Navas-Martin, a prominent microbiology and immunology professor at Drexel University College of Medicine, provides expert analysis on the variant's characteristics and public health implications. Her research focuses on immune responses to viral infections and the roles of spike proteins in coronavirus transmission and disease development, offering valuable insights into whether this emerging variant warrants heightened concern.

A heavily mutated COVID-19 variant designated BA.3.2, colloquially known as "Cicada," is spreading across over thirty U.S. states and gaining global traction. This variant emerged over a year ago but accelerated significantly in late 2024. BA.3.2 is distinguished by substantial genetic mutations in its spike protein, potentially enabling it to evade immunity acquired through vaccination or prior infection. Research published in the CDC's Morbidity and Mortality Weekly Report suggests these genetic modifications may reduce protective immunity. Consequently, public health officials are closely monitoring this "hyper-mutated" strain, which the World Health Organization designated as a variant under monitoring in December 2025. While overall COVID infections are declining nationally, BA.3.2's unique characteristics warrant continued epidemiological surveillance.

The Vaccine Adverse Event Reporting System (VAERS) serves as the nation's primary early warning system for monitoring the safety of FDA-approved vaccines and those authorized for public health emergencies. Co-managed by the CDC and FDA, VAERS accepts and analyzes reports of potential adverse events following vaccination from patients, healthcare providers, family members, and manufacturers. While healthcare providers and manufacturers are legally obligated to report certain events, submission of a report does not establish causation between a vaccine and an adverse event. When patterns suggest possible vaccine-associated health problems, the CDC and FDA conduct further investigation and implement necessary interventions. This comprehensive surveillance system enables continuous safety monitoring across the vaccinated population.

The European Centre for Disease Prevention and Control (ECDC) maintains a systematic approach to monitoring and classifying SARS-CoV-2 variants of concern as of April 24, 2026. The SAVE Working Group, comprising multidisciplinary experts in virology, bioinformatics, and epidemiology, convenes monthly to assess emerging variants' epidemiological impact across the EU/EEA and globally. ECDC employs three classification categories—variant under monitoring, variant of interest, and variant of concern—to communicate escalating risk levels. Evidence is continuously evaluated through epidemic intelligence and genomic surveillance, with classifications updated accordingly. Detailed surveillance data, including variant distribution and country-specific epidemiological updates, are published through the European Respiratory Virus Surveillance Summary, supporting coordinated public health response efforts.

A comprehensive safety evaluation of the mRNA-1273 COVID-19 vaccine, published in Human Vaccines & Immunotherapeutics, confirms a strong and well-characterized safety profile from clinical development through widespread global deployment. The review analyzed clinical trial data, pharmacovigilance findings, and real-world observational studies conducted across tens of thousands of participants. Preclinical studies demonstrated strong immunogenicity with acceptable tolerability, while clinical trials revealed a predictable, manageable reactogenicity profile featuring common mild-to-moderate transient adverse events such as injection-site pain, fatigue, headache, and myalgia. Serious adverse events occurred at comparable rates between vaccine and placebo groups. Post-authorization surveillance through global pharmacovigilance systems, including the Vaccine Adverse Event Reporting System and international regulatory databases, continued to validate the vaccine's safety profile during unprecedented global use.

The change, which officials acknowledged was made without input from an advisory committee that typically consults on the vaccine schedule, came after President Donald Trump in December asked the U.S. Department of Health and Human Services to review how peer nations approach vaccine recommendations and consider revising its guidance to align with theirs. HHS said its comparison to 20 peer nations found that the U.S. was an “outlier” in both the number of vaccinations and the number of doses it recommended to all children. Officials with the agency framed the change as a way to increase public trust by recommending only the most important vaccinations for children to receive.

Les États-Unis ont pris lundi une mesure sans précédent en réduisant le nombre de vaccins recommandés pour chaque enfant, laissant aux familles le choix d’autres vaccinations, telles que le vaccin contre la grippe, mais sans fournir de directives claires.

The A H3N2 flu virus, which historically caused the most hospitalizations and deaths in older people, is the most common strain in the US so far. Over 90% of analyzed H3N2 infections are a new subclade K variant, which differs from the strain in current flu vaccines. Flu seasons often don’t peak until January or February so health officials say it’s too early to know how big a problem the mismatch will be. The current flu season has already seen nine pediatric deaths, and emergency department visits for flu in children have exceeded last season's peak. The US Centers for Disease Control and Prevention estimates at least 11 million illnesses, 120,000 hospitalizations, and 5,000 deaths from flu so far this season, recommending vaccination for everyone aged six months and older.

Le 6 décembre dernier, une étude parue dans Nature a mis en évidence des erreurs de traduction de l’ARN messager modifié des vaccins anti-Covid. Ce dysfonctionnement a pour effet de produire un nombre indéterminé de protéines connues ou inconnues dans le corps, dont les effets pourraient être délétères. Suite à cette publication scientifique, l’avocat Jean-Pierre Joseph invite tous les vaccinés à porter plainte.

During the COVID-19 pandemic, human behavior change as a result of nonpharmaceutical interventions such as isolation may have induced directional selection for viral evolution. By combining previously published empirical clinical data analysis and multi-level mathematical modeling, we find that the SARS-CoV-2 variants selected for as the virus evolved from the pre-Alpha to the Delta variant had earlier and higher peak in viral load dynamics but a shorter duration of infection. Selection for increased transmissibility shapes the viral load dynamics, and the isolation measure is likely to be a driver of these evolutionary transitions.

The study analyzed the correlations between specific HLA alleles and the disease severity or T cell immune memory. The results showed that the alleles HLA-B*13:02 and -B*40:01 were associated with SARS-CoV-2 infection, which may be due to their rare peptide anchors.

The European Medicines Agency (EMA) monitors the safety of COVID-19 vaccines authorised in the European Union (EU) extremely carefully. With hundreds of millions of people already vaccinated in the EU, this enables the continued detection of any rare side effects.

The results suggest the existence of a batch-dependent safety signal for the BNT162b2 vaccine, and more studies are warranted to explore this preliminary observation and its consequences.

COVID-19 lockdowns were “a global policy failure of gigantic proportions,” according to this peer-reviewed new academic study. The draconian policy failed to significantly reduce deaths while imposing substantial social, cultural, and economic costs.